Advertisement

Topics

REVA to Hold Briefing Call on Q2 2015 Financial Results

20:00 EDT 5 Aug 2015 | Globe Newswire

SAN DIEGO, Aug. 06, 2015 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) will hold its quarterly briefing call to discuss operations and financial results through June 30, 2015. Robert Stockman, the Company’s Chairman and Chief Executive Officer, will host the call.

The call is scheduled for 4:00 p.m. PDT on Wednesday, August 12, 2015 (which is 9:00 a.m. AEST on Thursday, 13 August 2015) and may be accessed within the United States and Canada by dialing 1-877-312-5413 five minutes prior to the scheduled start time. Callers in Australia may access the call by dialing (02) 8223 9773. If you are asked to provide an access code, please spell out the word “REVA” to the operator and you will be connected promptly.

If you reside outside of the United States, Canada, or Australia, or if you prefer to access the audiocast through our website, please visit “Events & Presentations” under the “Investors” section of our website at www.revamedical.com, and click on the “listen to webcast” link. A replay of the audiocast will be available on our website after the call.

About REVA

REVA is a development stage medical device company located in San Diego, California, USA, that is focused on the development, testing, and eventual commercialization of its proprietary bioresorbable stents, which are called “scaffolds” because of their temporary nature. The Company’s scaffolds are currently in clinical studies and have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial intended commercial product, the FantomTM scaffold, has been designed to offer an ideal balance of thinness and strength, and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other products.

United States	
Investor & Media Enquiries:
REVA Medical, Inc.
Cheryl Liberatore	
Director, Communications
+1 858-966-3045	

Australia
Investor Enquiries:
Inteq Limited
Kim Jacobs
+61 2 9229 2700

Australia
Media Enquiries:
Buchan Consulting
Rebecca Wilson
+61 3 9866 4722
Annabel Murphy
+61 2 9237 2800

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "REVA to Hold Briefing Call on Q2 2015 Financial Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...

Complementary and Alternative Medicine
Alternative medicine are whole medical systems that did not fit with conventional medicine as they have completely different philosophies and ideas on the causes of disease, methods of diagnosis and approaches to treatment. Although often overlapping, co...

Radiology
Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...